Qiagen announced that it is considering its options after receiving "several conditional, [nonbinding] indications of interest" for its acquisition.
The company said in a statement on November 15 that it is starting discussions with interested parties, with the goal of exploring strategic alternatives that could provide greater value-creation opportunities than are possible as a standalone company.
According to a Bloomberg report, Thermo Fisher Scientific approached Qiagen about a deal, sending Qiagen stock soaring on November 15 to reflect a valuation of $8.3 billion. Thermo Fisher was not immediately available for comment.
